Recurrent gene fusions in prostate cancer
US9926602B2 · kind B2 · utility
0Cited by
54References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 2014 |
| Grant date | Mar 27, 2018 |
| Priority date | — |
| Expiry date | Jun 11, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.